Loading...
•
Sep 30, 2022
Vistagen Q2 2023 Earnings Report
Vistagen's Q2 2023 financial results were reported, and a corporate update was provided.
Key Takeaways
Vistagen reported a net loss of $17.5 million for the second quarter of fiscal year 2023, with cash and cash equivalents of $35.3 million at the end of the quarter. The company is preparing to restart the PALISADE-2 Phase 3 trial for PH94B in social anxiety disorder and plans to meet with the FDA regarding the next steps in Phase 3 development.
Independent data analysis supports restarting the PALISADE-2 Phase 3 study of PH94B in social anxiety disorder.
Preliminary data from the PALISADE Open Label Study demonstrates potential for PH94B to help individuals suffering from social anxiety disorder.
Vistagen submitted a U.S. Investigational New Drug application for a Phase 1 study to facilitate entering Phase 2B development of PH10 in major depressive disorder.
Enrollment completed in exploratory Phase 2A trial of PH94B in adjustment disorder with anxiety, with topline results anticipated in the first quarter of calendar 2023.